Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: | Keytruda |
Active Ingredient: | Pembrolizumab 25mg/mL |
Dosage Form: | Concentrate for infusion |
New Zealand Sponsor: | Merck Sharp & Dohme (New Zealand) Limited |
Manufacturer: | MSD International GmbH (Ireland), Carlow, Ireland |
Product: | Keytruda |
Active Ingredient: | Pembrolizumab 50mg |
Dosage Form: | Powder for infusion |
New Zealand Sponsor: | Merck Sharp & Dohme (New Zealand) Limited |
Manufacturer: | MSD International GmbH, Innishannon, Ireland |
Product: | Yaz |
Active Ingredients: | Drospirenone 3mg Ethinylestradiol betadex clathrate equivalent to ethinylestradiol 0.02mg |
Dosage Form: | Tablet |
New Zealand Sponsor: | Bayer New Zealand Limited |
Manufacturers: | Bayer Weimar GmbH und Co KG, Weimar, Germany Bayer AG, Leverkusen, Germany |
Dated this 19th day of July 2019.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).